As of Mar 19, 2025, the Lexeo Therapeutics stock's PE ratio is 0.17. This results from the current EPS of $17.54 and stock price of $3.04.
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2023 | N/A | N/A | $13.42 | -$12.4 |
2022 | N/A | N/A | N/A | -$36.36 |
2021 | N/A | N/A | N/A | -$32.6 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Sep 2024 | 0.52 | -80.3% | $9.04 | $17.54 |
Jun 2024 | 2.64 | N/A | $16.04 | $6.07 |
Mar 2024 | N/A | N/A | $15.68 | -$1.59 |
Dec 2023 | N/A | N/A | $13.42 | -$12.4 |
Sep 2023 | N/A | N/A | N/A | -$41.1 |
Jun 2023 | N/A | N/A | N/A | -$39.12 |
Mar 2023 | N/A | N/A | N/A | -$40.05 |
Dec 2022 | N/A | N/A | N/A | -$36.36 |
Sep 2022 | N/A | N/A | N/A | N/A |
Jun 2022 | N/A | N/A | N/A | N/A |
Dec 2021 | N/A | N/A | N/A | -$32.6 |
Stock name | PE ratio | Market cap |
---|---|---|
LXEO Lexeo Therapeutics Inc. | 0.16 | $91.26M |
NTLA Intellia Therapeutics Inc | N/A | $909.92M |
BLUE bluebird bio Inc | N/A | $37.04M |
CRSP CRISPR Therapeutics AG | N/A | $3.55B |
EDIT Editas Medicine Inc | N/A | $112.02M |
QURE uniQure NV | N/A | $740.85M |
RGNX REGENXBIO Inc | N/A | $410.46M |
SGMO Sangamo Therapeutics Inc | N/A | $189.9M |
ADVM Adverum Biotechnologies Inc | N/A | $116.7M |
BEAM Beam Therapeutics Inc | N/A | $1.92B |
VERV Verve Therapeutics Inc | N/A | $481.27M |
As of Mar 19, 2025, LXEO stock has a price to earnings ratio of 0.17.
LXEO's stock price is trading at a lower multiple of earnings, which is why its PE ratio of 0.17 is considered low.
You can calculate the PE ratio by dividing the most recent stock price by the trailing twelve months EPS. As of today (Mar 19, 2025), Lexeo Therapeutics's stock price is $3.04. The earnings per share for the trailing twelve months (TTM) ending Sep 2024 is $17.54. Therefore, Lexeo Therapeutics's P/E ratio for today is 0.17. PE RATIO(0.17) = STOCK PRICE($3.04) / TTM EPS($17.54)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.